Clinical Characteristics, Long-Term Pharmacokinetics, and Outcomes in Kidney Transplant Recipients from an African Tertiary Centre: A 10-Year Single-Centre Retrospective Review
Authors:
- Sadiq Aliyu HussainiSHSadiq Aliyu Hussaini
- Caroline DickensCDCaroline Dickens
- Confidence MakgoroCMConfidence Makgoro
- Therese Dix-PeekTDTherese Dix-Peek
- Badar MunirBMBadar Munir
- Jeevan PerumalaJPJeevan Perumala
- Simran PatelSPSimran Patel
- Qaiser GoolamQGQaiser Goolam
- Graham PagetGPGraham Paget
- Bala WaziriBWBala Waziri
- Raquel DuarteRDRaquel Duarte
Open Access
- 21 January 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 132
Abstract
Background: Kidney transplantation outcomes in resource-limited settings remain underreported. This 10-year retrospective review examined the clinical characteristics, long-term pharmacokinetics, and outcomes of kidney transplant recipients at a South African public hospital. Methods: Data from kidney transplant recipients between January 2012 and December 2022 were analysed. Graft and patient survival were assessed using Kaplan–Meier analysis. Cox proportional hazards models were used to evaluate the associations between clinical and pharmacokinetic variables and outcomes. Results: The one- and five-year graft survival rates were 87.9% and 65.6%, respectively. Acute rejection, as confirmed by biopsy, was associated with graft failure (HR, 2.46; p = 0.010). Increasing recipient age at transplantation increased the graft failure risk by about 5.0% per year (HR: 1.05, p = 0.006). Tacrolimus trough and normalised trough levels were lower in the graft loss group 73% and 93% of the time, respectively, despite similar tacrolimus doses. Whereas achieving optimal tacrolimus concentration did not significantly affect graft survival, maintaining a haemoglobin level >10 g/dL improved the chances of 3-, 4-, and 5-year graft survival (p-value, 0.001, 0.001, and <0.001, respectively). Patient survival rates were more favourable than graft survival rates. The 1-year and 5-year patient survival rates were 90.0% and 77.4%, respectively. Conclusions: This study offers insights into transplant outcomes in low-resource public health settings. The findings emphasise the impact of rejection and age on the risk of graft failure and the significance of maintaining adequate haemoglobin levels after transplantation. The results also indicate the need for more nuanced and personalised approaches to tacrolimus monitoring in the long-term following transplantation.Keywords
This publication has 32 references indexed in Scilit:
- Kidney transplantation in low- and middle-income countries: the Transplant Links experiencePediatric Nephrology, 2023
- P1706THE GRAFT SURVIVAL OF KIDNEY TRANSPLANTATION ACCORDING TO ETHNICITY IN KIDNEY TRANSPLANT RECIPIENTSNephrology Dialysis Transplantation, 2020
- Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectivesTransplantation Reviews, 2020
- Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus ReportTherapeutic Drug Monitoring, 2019
- JC Virus and APOL1 Risk Alleles in Black South Africans With Hypertension-Attributed CKDKidney International Reports, 2019
- Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to knowJournal Of Nephrology, 2016
- Genotype-guided tacrolimus dosing in African-American kidney transplant recipientsThe Pharmacogenomics Journal, 2015
- Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritBritish Journal of Clinical Pharmacology, 2015
- Outcomes in African American Kidney Transplant Patients Receiving Tacrolimus and Mycophenolic Acid ImmunosuppressionTransplantation, 2013
- KDIGO clinical practice guideline for the care of kidney transplant recipients: a summaryKidney International, 2010